fda semaglutide compounding warning november 2025 Compounded "semaglutide" is not FDA-approved FDA Warns on Certain Forms

Additionally, new or worsening constipation accompanied by unexplained weight loss (beyond expected therapeutic weight reduction), persistent changes in stool caliber, or alternating constipation and diarrhea warrants evaluation to exclude structural or neoplastic causes, particularly in patients age 45 or older or those with family history of colorectal cancer

Thus, the magnitude of semaglutide-induced diuresis is lower, but not completely ablated, with loss of the VSMC GLP-1R

The majority of subjects experienced no change in medication during the dosing or 1-month follow-up period

Low serum glutathione peroxidase activity is associated with increased cardiovascular mortality in individuals with low HDLcs